Torii Pharmaceutical Co., Ltd.

TSE:4551 Stock Report

Market Cap: JP¥178.3b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Torii Pharmaceutical Future Growth

Future criteria checks 0/6

Torii Pharmaceutical's earnings are forecast to decline at 0.1% per annum while its annual revenue is expected to grow at 2.4% per year. EPS is expected to decline by 0.1% per annum. Return on equity is forecast to be 3.6% in 3 years.

Key information

-0.1%

Earnings growth rate

-0.11%

EPS growth rate

Pharmaceuticals earnings growth13.6%
Revenue growth rate2.4%
Future return on equity3.60%
Analyst coverage

Low

Last updated31 Jul 2025

Recent future growth updates

Recent updates

Analysis Article • May 07

Torii Pharmaceutical Co., Ltd. (TSE:4551) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Torii Pharmaceutical Co., Ltd. ( TSE:4551 ) shares have had a really impressive month, gaining 27% after a shaky period...
Analysis Article • Jan 22

Torii Pharmaceutical Co., Ltd.'s (TSE:4551) Business Is Yet to Catch Up With Its Share Price

When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 13x, you may consider Torii...

Earnings and Revenue Growth Forecasts

TSE:4551 - Analysts future estimates and past financials data (JPY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202768,5004,8003,2854,8101
12/31/202666,9003,0702,5903,9301
12/31/202567,5004,230-4,663-3,1031
6/30/202563,4965,4092,9633,164N/A
3/31/202561,6585,555N/AN/AN/A
12/31/202460,4265,0423,4593,639N/A
9/30/202458,8395,276N/AN/AN/A
6/30/202457,2485,2541,0891,256N/A
3/31/202456,2785,285N/AN/AN/A
12/31/202354,6384,119-3,339-3,123N/A
9/30/202352,7133,456N/AN/AN/A
6/30/202351,4933,18581265N/A
3/31/202349,7472,774N/AN/AN/A
12/31/202248,8963,9442,1392,420N/A
9/30/202248,8653,992N/AN/AN/A
6/30/202248,5343,9752,0662,424N/A
3/31/202248,0483,820N/AN/AN/A
12/31/202146,9873,374-530-156N/A
9/30/202144,9653,225N/AN/AN/A
6/30/202143,3982,939-226266N/A
3/31/202142,0283,069N/AN/AN/A
12/31/202041,7003,495-3,854-3,443N/A
9/30/202041,8503,409N/AN/AN/A
6/30/202042,1712,973-12,178-11,961N/A
3/31/202043,408-293N/AN/AN/A
12/31/201942,99827,36742,08042,499N/A
9/30/201948,32825,382N/AN/AN/A
6/30/201952,68425,81053,43254,047N/A
3/31/201957,78229,117N/AN/AN/A
12/31/201862,5511,164N/A8,259N/A
9/30/201863,9524,195N/AN/AN/A
6/30/201864,5964,505N/A7,124N/A
3/31/201864,4574,899N/AN/AN/A
12/31/201764,1354,718N/A6,349N/A
9/30/201762,1643,855N/AN/AN/A
6/30/201761,2833,117N/A4,699N/A
3/31/201760,0742,424N/AN/AN/A
12/31/201660,2062,839N/A3,402N/A
9/30/201661,3052,951N/AN/AN/A
6/30/201661,9573,378N/A3,136N/A
3/31/201662,8203,798N/AN/AN/A
12/31/201562,3783,527N/A4,940N/A
12/31/201458,0893,393N/A-812N/A
9/30/201457,1073,031N/A2,013N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4551's earnings are forecast to decline over the next 3 years (-0.1% per year).

Earnings vs Market: 4551's earnings are forecast to decline over the next 3 years (-0.1% per year).

High Growth Earnings: 4551's earnings are forecast to decline over the next 3 years.

Revenue vs Market: 4551's revenue (2.4% per year) is forecast to grow slower than the JP market (4.3% per year).

High Growth Revenue: 4551's revenue (2.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 4551's Return on Equity is forecast to be low in 3 years time (3.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/02 00:58
End of Day Share Price 2025/08/27 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Torii Pharmaceutical Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hidemaru YamaguchiCitigroup Inc
Kazuaki HashiguchiDaiwa Securities Co. Ltd.